The landscape of ITP therapy, especially in adults, has changed dramatically over the past 10 to 20 years, with a decrease in splenectomy and growing use of medical therapies, particularly rituximab and the TPO-RAs. The goals for ITP for the next 10 years include identifying treatment regimens that will ameliorate the long-term course of, or even cure, the disease and identifying biomarkers that would allow us to match treatments with a patient’s underlying pathophysiologic mechanisms to enhance response rates. I do believe that in the future, whether this is 5 years, 10 years, or 20 years away, we will have tests that will help us to understand the pathophysiology of ITP in each individual patient. This increased understanding will allow us to be better able to match treatment with pathophysiology, which will, in turn, improve response rates and patient outcomes. We are not there yet, but I think that is a goal for the future.